COX2/Cyclooxygenase 2 Rabbit pAb from ELK Biotechnology Read more ›
COX2/Cyclooxygenase 2 Rabbit pAb is a research-use antibody from ELK Biotechnology for studying COX2/Cyclooxygenase 2 in WB, IHC workflows with listed reactivity for Human. Specifications and supporting documents below should be reviewed when planning the experiment.
Prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2 or simply COX-2, is an enzyme that in humans is encoded by the PTGS2 gene. There are two isozymes of COX encoded by distinct gene products: a constitutive COX-1 (this enzyme) and an inducible COX-2, which differ in their regulation of expression and tissue distribution. The expression of these two transcripts is differentially regulated by relevant cytokines and growth factors. A splice variant of COX-1 termed COX-3 was identified in the CNS of dogs, but does not result in a functional protein in humans. Two smaller COX-1-derived proteins (the partial COX-1 proteins PCOX-1A and PCOX-1B) have also been discovered, but their precise roles are yet to be described.
| Validation evidence captions | Western blot analysis of Hela with COX2 Rabbit Polyclonal antibody diluted at 1:1,000. |
|---|
| Collaborator | ELK Biotechnology |
| Partner model | EA024 |
| Target | COX2/Cyclooxygenase 2 |
| Research areas | Antibody Research |
| Reactivity | Human |
| Applications | WB,IHC |
| Conjugation | Unconjugated |
| Dilution range | WB 1:1,000 IHC 1:100 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Immunogen | Synthetic Peptide |
| Concentration | 1mg/mL |
| Assay type | Antibody validation/application |
| Species | WB | IHC | IF | ELISA | IP | FCM | ChIP |
|---|---|---|---|---|---|---|---|
| Human |
| Species | Dilution | Notes |
|---|---|---|
| Human | WB 1:1 | — |
| Species | Dilution | Notes |
|---|
Collaborator meets ABMIUM quality standards and overall product performance standards have been met.
Quality management certification.
For research applications. Not for diagnostic use.
No customer reviews yet.
